NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that it has signed a deal to supply the Nestlé Institute of Health Sciences with its iCell and MyCell product lines.

The iCell portfolio includes cardiomyocytes, neurons, hepatocytes, endothelial cells, and other cell types in development, while the MyCell line includes cell products manufactured from donor samples using iPSC technology to make stem cells or differentiated cells from any individual.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.